Merck, Eisai to discontinue late-stage study for skin cancer
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Merck & Co Inc and Eisai Co Ltd said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for treatment of adults with unresectable or metastatic melanoma, as the trial did not show improvement in overall survival.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-722208811-b3d22c5e5c164942a1983f328bfe06be.jpg "How to Become a Retirement Super Saver")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-184827885-2--573b86c35f9b58723dbe24fa.jpg "<div>IPO vs. Staying Private: What's the Difference?</div>")